LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Search

Revvity Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

92.37 1.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

90.15

Max

92.59

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

47.923

77.256

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.3

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+22.38% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.30%

2.33%

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-486M

11B

Ankstesnė atidarymo kaina

90.42

Ankstesnė uždarymo kaina

92.37

Naujienos nuotaikos

By Acuity

21%

79%

41 / 374 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-09 21:36; UTC

Uždarbis

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

2025-11-09 21:22; UTC

Uždarbis

Australia's ANZ Bank Posts 10% Drop in Annual Profit

2025-11-10 00:00; UTC

Rinkos pokalbiai

India Inflation Poised to Hit New Low -- Market Talk

2025-11-09 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

2025-11-09 23:35; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

2025-11-09 21:05; UTC

Uždarbis

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

2025-11-09 21:04; UTC

Uždarbis

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

2025-11-09 21:03; UTC

Uždarbis

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

2025-11-09 20:49; UTC

Uždarbis

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

2025-11-09 20:49; UTC

Uždarbis

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

2025-11-09 20:45; UTC

Uždarbis

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

2025-11-09 20:45; UTC

Uždarbis

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

2025-11-09 20:42; UTC

Uždarbis

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

2025-11-09 20:42; UTC

Uždarbis

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

2025-11-09 20:41; UTC

Uždarbis

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

2025-11-09 20:41; UTC

Uždarbis

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

2025-11-09 20:39; UTC

Uždarbis

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

2025-11-09 20:39; UTC

Uždarbis

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

2025-11-09 20:38; UTC

Uždarbis

ANZ Keeps Dividend at A$0.83 >ANZ.AU

2025-11-09 20:38; UTC

Uždarbis

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

2025-11-09 20:38; UTC

Uždarbis

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

2025-11-08 13:10; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

2025-11-08 03:50; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

2025-11-08 03:41; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

2025-11-08 03:07; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

2025-11-07 22:36; UTC

Uždarbis

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

2025-11-07 22:22; UTC

Uždarbis

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

2025-11-07 22:03; UTC

Uždarbis

Constellation Software 3Q Rev $2.95B >CSU.T

2025-11-07 22:03; UTC

Uždarbis

Constellation Software 3Q Net $210M >CSU.T

2025-11-07 22:03; UTC

Uždarbis

Constellation Software 3Q EPS $9.89 >CSU.T

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

22.38% į viršų

12 mėnesių prognozė

Vidutinis 111.1 USD  22.38%

Aukščiausias 125 USD

Žemiausias 100 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

8

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

41 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat